Latest News of MFIN
Medallion Financial Corp.'s (NASDAQ:MFIN) top owners are individual investors with 48% stake, while 31% is held by institutions
Individual investors hold a significant 48% stake in Medallion Financial, giving them a strong influence on management decisions. Institutional investors make up 31%, while insiders like the President...
FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer
The FDA approved AstraZeneca's Imfinzi in combination with chemo for early-stage non-small cell lung cancer. Imfinzi showed significant benefits in reducing recurrence and progression events. The drug...
Medallion Financial (NASDAQ:MFIN) delivers shareholders notable 8.7% CAGR over 5 years, surging 23% in the last week alone
Medallion Financial Corp. (NASDAQ:MFIN) has seen a 36% share price rise over 5 years, below the market average. However, recent growth indicates improving profitability, with a 51% total shareholder r...
-
AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study
By Yahoo! Finance | 4 months agoAstraZeneca's Imfinzi failed to meet the primary endpoint in the ADJUVANT BR.31 trial for early-stage lung cancer. However, it showed positive results in bladder cancer and small-cell lung cancer tria...